Tazact 2.25 GM Injection Tazact 2.25 GM combines Piperacillin, an extended-spectrum ureidopenicillin antibiotic, with Tazobactam, a beta-lactamase inhibitor. Piperacillin prevents bacterial cell wall synthesis by targeting penicillin-binding proteins (PBPs), while Tazobactam inactivates beta-lactamase enzymes that would otherwise break down Piperacillin. It is indicated for treating moderate-to-severe bacterial infections, including intra-abdominal infections, skin and soft tissue infections, community-acquired and hospital-acquired pneumonia, gynecological infections, and febrile neutropenia.